Carter Gould
Stock Analyst at Barclays
(3.53)
# 978
Out of 4,479 analysts
154
Total ratings
54.17%
Success rate
2.12%
Average return
Main Sectors:
25 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BRNS Barinthus Biotherapeutics | Maintains: Overweight | $7 → $3 | $1.44 | +108.33% | 1 | Jun 13, 2024 | |
| GERN Geron | Initiates: Overweight | $9 | $4.17 | +115.83% | 1 | Jun 11, 2024 | |
| CYTK Cytokinetics | Maintains: Overweight | $100 → $95 | $54.84 | +73.23% | 2 | May 23, 2024 | |
| AMGN Amgen | Upgrades: Equal-Weight | $230 → $300 | $310.77 | -3.47% | 14 | May 3, 2024 | |
| NBIX Neurocrine Biosciences | Maintains: Overweight | $150 → $169 | $137.49 | +22.92% | 8 | May 2, 2024 | |
| GILD Gilead Sciences | Maintains: Equal-Weight | $80 → $76 | $68.40 | +11.11% | 12 | Apr 29, 2024 | |
| ABBV AbbVie | Maintains: Overweight | $195 → $187 | $165.96 | +12.68% | 12 | Apr 29, 2024 | |
| BMY Bristol-Myers Squibb Company | Maintains: Equal-Weight | $51 → $43 | $40.45 | +6.30% | 10 | Apr 26, 2024 | |
| BIIB Biogen | Maintains: Equal-Weight | $215 → $200 | $228.82 | -12.60% | 21 | Apr 25, 2024 | |
| SKIL Skillsoft | Maintains: Overweight | $25 → $20 | $12.90 | +55.04% | 5 | Apr 16, 2024 | |
| ACLX Arcellx | Maintains: Overweight | $62 → $73 | $53.25 | +37.09% | 4 | Feb 29, 2024 | |
| MRK Merck & Co. | Maintains: Overweight | $135 → $145 | $127.72 | +13.53% | 8 | Feb 2, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $935 → $1,020 | $1,044.66 | -2.36% | 10 | Jan 23, 2024 | |
| LLY Eli Lilly | Maintains: Overweight | $630 → $680 | $906.71 | -25.00% | 8 | Jan 23, 2024 | |
| ALLK Allakos | Maintains: Underweight | $1.5 → $1 | $0.84 | +18.96% | 4 | Jan 17, 2024 | |
| PFE Pfizer | Maintains: Equal-Weight | $34 → $28 | $27.83 | +0.61% | 11 | Dec 14, 2023 | |
| TVTX Travere Therapeutics | Maintains: Overweight | $31 → $12 | $8.09 | +48.33% | 3 | Sep 22, 2023 | |
| ALEC Alector | Maintains: Overweight | $14 → $12 | $4.34 | +176.50% | 2 | May 5, 2023 | |
| GOSS Gossamer Bio | Maintains: Equal-Weight | $2 → $1.5 | $0.96 | +56.28% | 5 | Mar 21, 2023 | |
| VOR Vor Biopharma | Maintains: Overweight | $26 → $15 | $0.91 | +1,541.14% | 2 | Nov 11, 2022 | |
| MTEM Molecular Templates | Maintains: Overweight | $68 → $15 | $1.16 | +1,193.10% | 2 | Nov 11, 2022 | |
| APLT Applied Therapeutics | Maintains: Equal-Weight | $2.5 → $2.25 | $4.35 | -48.28% | 4 | Aug 16, 2022 | |
| PAYC Paycom Software | Maintains: Equal-Weight | $392 → $380 | $142.17 | +167.29% | 1 | Jan 20, 2022 | |
| INCY Incyte | Downgrades: Neutral | n/a | $59.02 | - | 3 | Jan 16, 2019 | |
| VRTX Vertex Pharmaceuticals | Maintains: Neutral | n/a | $473.78 | - | 1 | Jul 26, 2018 |
Barinthus Biotherapeutics
Jun 13, 2024
Maintains: Overweight
Price Target: $7 → $3
Current: $1.44
Upside: +108.33%
Geron
Jun 11, 2024
Initiates: Overweight
Price Target: $9
Current: $4.17
Upside: +115.83%
Cytokinetics
May 23, 2024
Maintains: Overweight
Price Target: $100 → $95
Current: $54.84
Upside: +73.23%
Amgen
May 3, 2024
Upgrades: Equal-Weight
Price Target: $230 → $300
Current: $310.77
Upside: -3.47%
Neurocrine Biosciences
May 2, 2024
Maintains: Overweight
Price Target: $150 → $169
Current: $137.49
Upside: +22.92%
Gilead Sciences
Apr 29, 2024
Maintains: Equal-Weight
Price Target: $80 → $76
Current: $68.40
Upside: +11.11%
AbbVie
Apr 29, 2024
Maintains: Overweight
Price Target: $195 → $187
Current: $165.96
Upside: +12.68%
Bristol-Myers Squibb Company
Apr 26, 2024
Maintains: Equal-Weight
Price Target: $51 → $43
Current: $40.45
Upside: +6.30%
Biogen
Apr 25, 2024
Maintains: Equal-Weight
Price Target: $215 → $200
Current: $228.82
Upside: -12.60%
Skillsoft
Apr 16, 2024
Maintains: Overweight
Price Target: $25 → $20
Current: $12.90
Upside: +55.04%
Arcellx
Feb 29, 2024
Maintains: Overweight
Price Target: $62 → $73
Current: $53.25
Upside: +37.09%
Merck & Co.
Feb 2, 2024
Maintains: Overweight
Price Target: $135 → $145
Current: $127.72
Upside: +13.53%
Regeneron Pharmaceuticals
Jan 23, 2024
Maintains: Overweight
Price Target: $935 → $1,020
Current: $1,044.66
Upside: -2.36%
Eli Lilly
Jan 23, 2024
Maintains: Overweight
Price Target: $630 → $680
Current: $906.71
Upside: -25.00%
Allakos
Jan 17, 2024
Maintains: Underweight
Price Target: $1.5 → $1
Current: $0.84
Upside: +18.96%
Pfizer
Dec 14, 2023
Maintains: Equal-Weight
Price Target: $34 → $28
Current: $27.83
Upside: +0.61%
Travere Therapeutics
Sep 22, 2023
Maintains: Overweight
Price Target: $31 → $12
Current: $8.09
Upside: +48.33%
Alector
May 5, 2023
Maintains: Overweight
Price Target: $14 → $12
Current: $4.34
Upside: +176.50%
Gossamer Bio
Mar 21, 2023
Maintains: Equal-Weight
Price Target: $2 → $1.5
Current: $0.96
Upside: +56.28%
Vor Biopharma
Nov 11, 2022
Maintains: Overweight
Price Target: $26 → $15
Current: $0.91
Upside: +1,541.14%
Molecular Templates
Nov 11, 2022
Maintains: Overweight
Price Target: $68 → $15
Current: $1.16
Upside: +1,193.10%
Applied Therapeutics
Aug 16, 2022
Maintains: Equal-Weight
Price Target: $2.5 → $2.25
Current: $4.35
Upside: -48.28%
Paycom Software
Jan 20, 2022
Maintains: Equal-Weight
Price Target: $392 → $380
Current: $142.17
Upside: +167.29%
Incyte
Jan 16, 2019
Downgrades: Neutral
Price Target: n/a
Current: $59.02
Upside: -
Vertex Pharmaceuticals
Jul 26, 2018
Maintains: Neutral
Price Target: n/a
Current: $473.78
Upside: -